Dr. Barrientos on the Impact of Combinations in CLL

Jacqueline C. Barrientos, MD
Published: Wednesday, Mar 14, 2018



Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia (CLL).

Combinations offer the opportunity to treat certain patients who would not be optimally treated with the currently available regimens, says Barrientos. This is particularly true for patients older than 65, as they traditionally do not do well with a chemotherapy regimen like fludarabine, cyclophosphamide, and rituximab (Rituxan). Barrientos says that even patients in their 80s can undergo combination therapy.

Combination studies like TAP CLARITY, which evaluated ibrutinib (Imbruvia) plus venetoclax (Venclexta) in patients with relapsed/refractory CLL, have shown that combinations elicit deep responses with no increase in toxicity. Based on studies like these, Barrientos says that there is a possibility of a future with chemotherapy-free regimens for patients with CLL. This will provide the opportunity for patients to achieve deeper responses so that they do not need to be on a drug indefinitely, she adds.


Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia (CLL).

Combinations offer the opportunity to treat certain patients who would not be optimally treated with the currently available regimens, says Barrientos. This is particularly true for patients older than 65, as they traditionally do not do well with a chemotherapy regimen like fludarabine, cyclophosphamide, and rituximab (Rituxan). Barrientos says that even patients in their 80s can undergo combination therapy.

Combination studies like TAP CLARITY, which evaluated ibrutinib (Imbruvia) plus venetoclax (Venclexta) in patients with relapsed/refractory CLL, have shown that combinations elicit deep responses with no increase in toxicity. Based on studies like these, Barrientos says that there is a possibility of a future with chemotherapy-free regimens for patients with CLL. This will provide the opportunity for patients to achieve deeper responses so that they do not need to be on a drug indefinitely, she adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x